Cook Medical Receives Vizient Contract for Endoscopy Devices

Cook Medical has received a contract with Vizient for endoscopy devices. This new agreement will allow Cook to continue to offer our endoscopy devices at negotiated pricing terms to healthcare facilities that are members of Vizient. With the agreement from Vizient, which is the largest member-driven healthcare performance improvement company in the country, Cook looks forward to making endoscopy products more accessible for physicians and patients across the United States.

For almost 60 years, Cook Medical has collaborated with physicians to develop innovative devices to improve lives around the world. We brought our pioneering model for minimally invasive devices to the field of gastrointestinal (GI) endoscopy to diagnose and treat diseases throughout the gastrointestinal tract. The FDA has granted multiple Cook Endoscopy products FDA Breakthrough Device Designations, including our technologies for hemostasis and endoscopic ultrasound. Now, with this contract, endoscopy products will be more accessible to more patients.

This new Vizient agreement becomes effective April 1, 2023. The agreement will include Cook’s full line of endoscopy medical devices, including Hemospray® Endoscopic Hemostat. The contract will also include products from the following product categories:

  • Biliary access (long wire & short wire)
  • Biliary / pancreatic therapy
  • Biopsy, cytology & polypectomy
  • Extraction, dilation, drainage stenting
  • Stricture management
  • Tissue management
  • Esophageal, gastric, colonic
  • Enteroscopy
  • Hemostasis
  • Endoscopic ultrasound
  • Endobronchial ultrasound
  • Endohepatology
  • Endosurgery

“We are honored to have been chosen as an Endoscopy contracted supplier with Vizient. With over 40 years of expertise in the gastroenterology specialty, Cook Medical looks forward to continuing to work with Vizient members and the physicians that treat patients with our endoscopy medical devices,” said Rick Simms, Cook Medical National GPO Account Executive.

Contracting with Cook Medical has several benefits for hospital systems and healthcare facilities. Cook is dedicated to responsible product creation and consumption as we care for the planet. To learn more about our earth-conscious values, you can read about our initiatives here.

To learn more about our breakthrough products and other initiatives, visit Cook’s Endoscopy page.

 

 

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.